abstract
OBJECTIVE:
To exclude minimal residual disease in remaining
ovarian tissue after harvesting the
ovarian cortex for
cryopreservation, by means of a tailor-made approach.
DESIGN:
Retrospective case series.
SETTING:
Hospital laboratory.
PATIENT(S):
We evaluated the
ovarian and tubal tissue from 47
cancer patients (breast
cancer, [non-]Hodgkin lymphoma; osteo-, Ewing, myxoid lipo-, and oropharyngeal synovial sarcoma; cervical, rectal, and esophageal
cancer), who had stored
ovarian tissue for fertility preservation.
INTERVENTION(S):
Immunohistochemistry
(IHC) with tumor-related antibodies and genetic mutation analysis were
performed to detect micrometastases by multiple sectioning at three
levels of the paraffin-embedded formalin-fixed material. Molecular
assays were performed with the use of tissue between these three levels
of sectioning.
MAIN OUTCOME MEASURE(S):
Detection of micrometastases in ovaries.
RESULT(S):
We analyzed 847
ovarian
slides to detect isolated tumor cells (ITCs) or micrometastases by IHC.
In only one case (1/47) were ITCs detected in the fallopian tube. That
patient had an intra-abdominal metastatic esophageal carcinoma.
Additional DNA analyses of breast and rectal
cancer, Ewing sarcoma, and human papilloma virus in cervical patients did not show evidence of micrometastases in the
ovarian tissue.
CONCLUSION(S):
The tailor-made approach consisted of patient-specific tumor markers which were used to search for
ovarian
micrometastases.
We found evidence of metastatic disease within the
fallopian tube of a patient with intraperitoneal metastatic esophageal
adenocarcinoma.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.